General Information of the Protein
Protein ID
PT00861
Protein Name
Mitogen-activated protein kinase 14
Secondarily
Protein Name
Cytokine suppressive anti-inflammatory drug-binding protein
MAP kinase MXI2
MAX-interacting protein 2
Mitogen-activated protein kinase p38 alpha
Stress-activated protein kinase 2a
Gene Name
MAPK14
Secondarily
Gene Name
CSBP
CSBP1
CSBP2
CSPB1
MXI2
SAPK2A
Sequence
MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
CMGC protein kinase group
>
CMGC protein kinase MAPK family
>
CMGC protein kinase p38 subfamily
Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1 (PubMed:9687510, PubMed:9792677). RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery (PubMed:9687510, PubMed:9792677). On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2 (PubMed:11154262). MAPK14 interacts also with casein kinase II, leading to its activation through autophosphorylation and further phosphorylation of TP53/p53 (PubMed:10747897). In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin ligase SIAH2, regulating its activity towards EGLN3 (PubMed:17003045). MAPK14 may also inhibit the lysosomal degradation pathway of autophagy by interfering with the intracellular trafficking of the transmembrane protein ATG9 (PubMed:19893488). Another function of MAPK14 is to regulate the endocytosis of membrane receptors by different mechanisms that impinge on the small GTPase RAB5A. In addition, clathrin-mediated EGFR internalization induced by inflammatory cytokines and UV irradiation depends on MAPK14-mediated phosphorylation of EGFR itself as well as of RAB5A effectors (PubMed:16932740). Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17 (PubMed:20188673). Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A (PubMed:9430721, PubMed:9858528, PubMed:10330143). The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required for binding to 14-3-3 proteins and leads to initiation of a G2 delay after ultraviolet radiation (PubMed:11333986). Phosphorylates TIAR following DNA damage, releasing TIAR from GADD45A mRNA and preventing mRNA degradation (PubMed:20932473). The p38 MAPKs may also have kinase-independent roles, which are thought to be due to the binding to targets in the absence of phosphorylation. Protein O-Glc-N-acylation catalyzed by the OGT is regulated by MAPK14, and, although OGT does not seem to be phosphorylated by MAPK14, their interaction increases upon MAPK14 activation induced by glucose deprivation. This interaction may regulate OGT activity by recruiting it to specific targets such as neurofilament H, stimulating its O-Glc-N-acylation. Required in mid-fetal development for the growth of embryo-derived blood vessels in the labyrinth layer of the placenta. Also plays an essential role in developmental and stress-induced erythropoiesis, through regulation of EPO gene expression (PubMed:10943842). Isoform MXI2 activation is stimulated by mitogens and oxidative stress and only poorly phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early onset of apoptosis. Phosphorylates S100A9 at 'Thr-113' (PubMed:15905572). Phosphorylates NLRP1 downstream of MAP3K20/ZAK in response to UV-B irradiation and ribosome collisions, promoting activation of the NLRP1 inflammasome and pyroptosis (PubMed:35857590).
    Show/Hide
Uniprot ID
Primary ID:
Q16539

Secondarily ID:
A6ZJ92
A8K6P4
B0LPH0
B5TY32
O60776
Q13083
Q14084
Q8TDX0
    Show/Hide
Ensembl ID
ENSG00000112062
HGNC ID
HGNC:6876
Subcellular Location
Cytoplasm
Nucleus
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000068 , A-549
Compound ID Compound Name Compound Formula
CP0132019
US10568884, Cpd 32
   Show/Hide
C22H27ClFN7O4S
 1
1
IC50 = 690 nM
   TI
   LI
   LO
   TS
CP0230652
US10568884, Cpd 9
   Show/Hide
C22H27ClFN7O4S
 1
1
IC50 = 2200 nM
   TI
   LI
   LO
   TS
CP0354458
US10568884, Cpd 29
   Show/Hide
C18H20ClFN6O2S
 1
1
IC50 = 17000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0171417
7-(1-tert-butylpiperidin-4-yl)-1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H28Cl2F2N2O
 2
1 IC50 = 0.08 nM
2 IC50 = 0.14 nM
CP0251148
7-(1-tert-butylpiperidin-4-yl)-5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H29Cl3N2O
 1
1 IC50 = 0.1 nM
CP0018897
1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea
   Show/Hide
C31H37N5O3
 22
1 IC50 = 0.1 nM
2 IC50 = 10 nM
3 IC50 = 12 nM
4 IC50 = 17 nM
5 IC50 = 20 nM
6 IC50 = 44 nM
7 IC50 = 89 nM
8 IC50 = 398.11 nM
9 Kd = 0.046 nM
10 Kd = 0.098 nM
11 Kd = 0.1 nM
12 Kd = 0.16 nM
13 Kd = 0.24 nM
14 Kd = 0.37 nM
15 Kd = 0.45 nM
16 Kd = 1 nM
17 Kd = 1.3 nM
18 Kd = 12 nM
19 Ki = 0.097 nM
20 Ki = 6.4 nM
21 Ki = 22 nM
22 Ki < 46 nM
CP0081909
13-(3-benzamido-4-fluoroanilino)-N-(2-morpholin-4-ylethyl)-2-oxotricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene-5-carboxamide
   Show/Hide
C35H33FN4O4
 5
1 IC50 = 0.2 nM
2 IC50 = 31 nM
3 IC50 = 38 nM
4 IC50 ~ 0.2 nM
5 IC50 ~ 14.9 nM
CP0161813
5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-7-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)quinolin-2(1H)-one
   Show/Hide
C30H26Cl3FN2O
 1
1 IC50 = 0.26 nM
CP0132192
7-(1-tert-butylpiperidin-4-yl)-5-(2-chloro-4-fluorophenyl)-1-(2,6-difluorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H28ClF3N2O
 1
1 IC50 = 0.3 nM
CP0320088
7-(1-tert-butylpiperidin-4-yl)-5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H28Cl3FN2O
 1
1 IC50 = 0.31 nM
CP0320087
7-(1-tert-butylpiperidin-4-yl)-5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-1,6-naphthyridin-2(1H)-one
   Show/Hide
C29H27Cl3FN3O
 1
1 IC50 = 0.38 nM
CP0171231
7-(8-aza-bicyclo[3.2.1]octan-3-yl)-5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)quinolin-2(1H)-one
   Show/Hide
C28H22Cl3FN2O
 1
1 IC50 = 0.45 nM
CP0092017
5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-7-(8-isopropyl-8-aza-bicyclo[3.2.1]octan-3-yl)quinolin-2(1H)-one
   Show/Hide
C31H28Cl3FN2O
 1
1 IC50 = 0.51 nM
CP0099448
7-(1-tert-butylpiperidin-4-yl)-1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-1,6-naphthyridin-2(1H)-one
   Show/Hide
C29H27Cl2F2N3O
 1
1 IC50 = 0.51 nM
CP0184162
N-[2,4-difluoro-5-[[14-(2-hydroxyethylcarbamoyl)-2-oxo-6-tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaenyl]amino]phenyl]thiophene-2-carboxamide
   Show/Hide
C29H23F2N3O4S
 2
1 IC50 = 0.6 nM
2 IC50 = 34.7 nM
CP0196821
N-[4-fluoro-3-[[14-(2-morpholin-4-ylethylcarbamoyl)-2-oxo-6-tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaenyl]amino]phenyl]thiophene-2-carboxamide
   Show/Hide
C33H31FN4O4S
 2
1 IC50 = 0.6 nM
2 IC50 = 35 nM
CP0370191
5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-7-(8-methyl-8-aza-bicyclo[3.2.1]octan-3-yl)quinolin-2(1H)-one
   Show/Hide
C29H24Cl3FN2O
 1
1 IC50 = 0.61 nM
CP0264600
2-(4-(5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-2-oxo-1,2-dihydroquinolin-7-yl)piperidin-1-yl)-2-methylpropanoic acid
   Show/Hide
C30H26Cl3FN2O3
 1
1 IC50 = 0.84 nM
CP0143445
3-(3-benzamido-4-fluoroanilino)-N-(2-morpholin-4-ylethyl)-11-oxo-6H-benzo[c][1]benzoxepine-9-carboxamide
   Show/Hide
C34H31FN4O5
 2
1 IC50 = 1 nM
2 IC50 = 463.8 nM
CP0143449
N-[2,4-difluoro-5-[[14-(2-morpholin-4-ylethylcarbamoyl)-2-oxo-6-tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaenyl]amino]phenyl]thiophene-2-carboxamide
   Show/Hide
C33H30F2N4O4S
 2
1 IC50 = 1 nM
2 IC50 = 43 nM
CP0251076
7-(1-tert-butyl-1,2,3,6-tetrahydropyridin-4-yl)-5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H26Cl3FN2O
 1
1 IC50 = 1.15 nM
CP0320085
(2S)-2-(4-(5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-2-oxo-1,2-dihydroquinolin-7-yl)piperidin-1-yl)propanoic acid
   Show/Hide
C29H24Cl3FN2O3
 1
1 IC50 = 1.3 nM
CP0184160
methyl 3-[2,4-difluoro-5-(thiophene-2-carbonylamino)anilino]-11-oxo-6H-benzo[c][1]benzoxepine-9-carboxylate
   Show/Hide
C27H18F2N2O5S
 1
1 IC50 = 1.3 nM
CP0303440
N-[5-[[14-(2,3-dihydroxypropylcarbamoyl)-2-oxo-6-tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaenyl]amino]-2-fluorophenyl]thiophene-2-carboxamide
   Show/Hide
C30H26FN3O5S
 2
1 IC50 = 1.4 nM
2 IC50 = 35.7 nM
CP0171229
7-(1-tert-butylpiperidin-4-yloxy)-5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H29Cl3N2O2
 1
1 IC50 = 1.6 nM
CP0426400
3-[4-fluoro-3-(thiophene-2-carbonylamino)anilino]-N-(2-morpholin-4-ylethyl)-11-oxo-6H-benzo[c][1]benzoxepine-9-carboxamide
   Show/Hide
C32H29FN4O5S
 2
1 IC50 = 1.6 nM
2 IC50 = 192.1 nM
CP0320084
7-(1-tert-butylpiperidin-4-yloxy)-1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H28Cl2F2N2O2
 1
1 IC50 = 1.87 nM
CP0081900
N-(2,3-dihydroxypropyl)-3-[4-fluoro-3-(thiophene-2-carbonylamino)anilino]-11-oxo-6H-benzo[c][1]benzoxepine-9-carboxamide
   Show/Hide
C29H24FN3O6S
 2
1 IC50 = 2 nM
2 IC50 = 168.5 nM
CP0320086
(2R)-2-(4-(5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-2-oxo-1,2-dihydroquinolin-7-yl)piperidin-1-yl)propanoic acid
   Show/Hide
C29H24Cl3FN2O3
 1
1 IC50 = 3.2 nM
CP0030365
5-amino-N-[[4-(3-cyclohexylpropylcarbamoyl)phenyl]methyl]-1-phenylpyrazole-4-carboxamide
   Show/Hide
C27H33N5O2
 5
1 IC50 = 5 nM
2 IC50 ~ 3.7 nM
3 IC50 ~ 5 nM
4 IC50 < 1000 nM
5 IC50 < 333000 nM
CP0047160
3-(3-bromo-4-(2,4-difluorobenzyloxy)-6-methyl-2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide
   Show/Hide
C22H19BrF2N2O3
 3
1 IC50 = 5.8 nM
2 Ki = 2.9 nM
3 Ki = 5.8 nM
CP0030881
SR-302
   Show/Hide
C32H42N6O5S
 4
1 IC50 = 6.2 nM
2 IC50 = 125 nM
3 IC50 ~ 6.2 nM
4 IC50 ~ 125 nM
CP0251147
methyl 2-[4-[5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-2-oxoquinolin-7-yl]piperidin-1-yl]-2-methylpropanoate
   Show/Hide
C31H28Cl3FN2O3
 1
1 IC50 = 6.7 nM
CP0319508
7-(1-tert-butylpiperidin-4-yloxy)-5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H28Cl3FN2O2
 1
1 IC50 = 7.1 nM
CP0370189
methyl 2-[4-[5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-2-oxoquinolin-7-yl]piperidin-1-yl]propanoate
   Show/Hide
C30H26Cl3FN2O3
 1
1 IC50 = 8.1 nM
CP0016295
4-[4-(4-fluorophenyl)-2-(4-methanesulfinylphenyl)-1H-imidazol-5-yl]pyridine
   Show/Hide
C21H16FN3OS
 36
1 IC50 = 10 nM
2 IC50 = 19 nM
3 IC50 = 20 nM
4 IC50 = 25 nM
5 IC50 = 30 nM
6 IC50 = 35 nM
7 IC50 = 37 nM
8 IC50 = 38 nM
9 IC50 = 39 nM
10 IC50 = 40 nM
11 IC50 = 41 nM
12 IC50 = 44 nM
13 IC50 = 45 nM
14 IC50 = 48 nM
15 IC50 = 50 nM
16 IC50 = 55 nM
17 IC50 = 62 nM
18 IC50 = 65 nM
19 IC50 = 68 nM
20 IC50 = 70 nM
21 IC50 = 72 nM
22 IC50 = 100 nM
23 IC50 = 159 nM
24 IC50 = 273 nM
25 IC50 = 290 nM
26 IC50 = 462 nM
27 IC50 = 500 nM
28 IC50 = 723 nM
29 IC50 = 2000 nM
30 IC50 = 6000 nM
31 IC50 = 7000 nM
32 Kd = 4.1 nM
33 Kd = 12 nM
34 Kd = 17 nM
35 Ki = 18 nM
36 Ki = 57 nM
CP0077880
7-(1-tert-butylpiperidin-4-yloxy)-5-(2,4-difluorophenyl)-1-(2,6-difluorophenyl)quinolin-2(1H)-one
   Show/Hide
C30H28F4N2O2
 1
1 IC50 = 10.5 nM
CP0060853
4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine
   Show/Hide
C19H20FN5O
 3
1 IC50 = 19 nM
2 IC50 = 40 nM
3 Ki = 36 nM
CP0020942
N-[3-[3-(3-chloro-4-methoxyphenyl)-4-pyridin-4-ylpyrazol-1-yl]phenyl]-3-(trifluoromethyl)benzamide
   Show/Hide
C29H20ClF3N4O2
 1
1 IC50 = 22 nM
CP0088516
3-[5-chloro-4-[(2,4-difluorophenyl)methoxy]-6-oxopyrimidin-1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
   Show/Hide
C21H18ClF2N3O4
 2
1 IC50 = 29 nM
2 Ki = 193 nM
CP0112104
N-[4-methyl-3-[3-[4-(methylamino)-1,3,5-triazin-2-yl]pyridin-2-yl]oxyphenyl]-3-(1,1,2,2-tetrafluoroethoxy)benzamide
   Show/Hide
C25H20F4N6O3
 1
1 IC50 = 47 nM
CP0035439
6-Methyl-biphenyl-3,4'-dicarboxylic acid 3-cyclopropylamide 4'-cyclopropylmethyl-amide
   Show/Hide
C22H24N2O2
 7
1 IC50 = 75 nM
2 IC50 = 199.53 nM
3 IC50 = 1584.89 nM
4 Ki = 9 nM
5 Ki = 10 nM
6 Ki = 12 nM
7 Ki = 12.59 nM
CP0019162
N-[3-[4-(cyclopropylmethylcarbamoyl)phenyl]-4-methylphenyl]furan-3-carboxamide
   Show/Hide
C23H22N2O3
 3
1 IC50 = 96 nM
2 Ki = 6 nM
3 Ki = 15 nM
CP0034776
1-(2,4-difluorophenyl)-4-{[3-(pyridin-3-yl)phenyl]carbonyl}-1H-pyrazol-5-amine
   Show/Hide
C21H14F2N4O
 1
1 IC50 = 180 nM
CP0166803
1-[2-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenyl)ethyl]cyclopentan-1-ol
   Show/Hide
C23H24FN3O2
 1
1 IC50 = 230 nM
CP0025247
1-[3,5-bis(trifluoromethyl)phenyl]-3-[3-[3-(3-chloro-4-methoxyphenyl)-4-pyridin-4-ylpyrazol-1-yl]phenyl]urea
   Show/Hide
C30H20ClF6N5O2
 1
1 IC50 = 307 nM
CP0216153
1-(2,4-difluorophenyl)-4-{[3-(pyridin-4-yl)phenyl]carbonyl}-1H-pyrazol-5-amine
   Show/Hide
C21H14F2N4O
 1
1 IC50 = 310 nM
CP0741196
[5-amino-1-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-[3-(1-oxypyridin-3-yl)phenyl]methanone
   Show/Hide
C21H14F2N4O2
 1
1 IC50 = 340 nM
CP0212339
4-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenyl)-2-methylbutan-2-ol
   Show/Hide
C21H22FN3O2
 1
1 IC50 = 590 nM
CP0035382
(2S)-3-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenoxy)propane-1,2-diol
   Show/Hide
C19H18FN3O4
 2
1 IC50 = 700 nM
2 Kd = 200 nM
CP0051870
1-(4-fluorophenyl)-4-{[3-(pyridin-3-yl)phenyl]carbonyl}-1H-pyrazol-5-amine
   Show/Hide
C21H15FN4O
 1
1 IC50 = 780 nM
CP0263416
1-(4-fluorophenyl)-4-{[3-(2-methanesulfonylethyl)phenyl]carbonyl}-1H-pyrazol-5-amine
   Show/Hide
C19H18FN3O3S
 1
1 IC50 = 790 nM
CP0272393
2-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenyl)ethan-1-ol
   Show/Hide
C18H16FN3O2
 1
1 IC50 = 850 nM
CP0223364
1-(4-fluorophenyl)-4-{[4-(pyridin-3-yl)phenyl]carbonyl}-1H-pyrazol-5-amine
   Show/Hide
C21H15FN4O
 1
1 IC50 = 980 nM
CP0324038
(5-Amino-1-O-tolyl-1H-pyrazol-4-yl)phenylmethanone
   Show/Hide
C17H15N3O
 1
1 IC50 = 1080 nM
CP0334489
4-benzoyl-1-(4-fluorophenyl)-1H-pyrazol-5-amine
   Show/Hide
C16H12FN3O
 1
1 IC50 = 1100 nM
CP0216152
(2R)-3-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenoxy)propane-1,2-diol
   Show/Hide
C19H18FN3O4
 1
1 IC50 = 1200 nM
CP0303024
2-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenyl)ethane-1-sulfonamide
   Show/Hide
C18H17FN4O3S
 1
1 IC50 = 1250 nM
CP0035426
1-(4-fluorophenyl)-4-({3-[2-(morpholin-4-yl)ethoxy]phenyl}carbonyl)-1H-pyrazol-5-amine
   Show/Hide
C22H23FN4O3
 1
1 IC50 = 1270 nM
CP0216154
1-(4-fluorophenyl)-4-{[3-(pyridin-4-yl)phenyl]carbonyl}-1H-pyrazol-5-amine
   Show/Hide
C21H15FN4O
 1
1 IC50 = 1280 nM
CP0272394
1-(4-fluorophenyl)-4-({3-[3-(piperidin-1-yl)prop-1-yn-1-yl]phenyl}carbonyl)-1H-pyrazol-5-amine
   Show/Hide
C24H23FN4O
 1
1 IC50 = 1320 nM
CP0206432
1-(4-fluorophenyl)-4-({3-[2-(4-methylpiperazin-1-yl)ethyl]phenyl}carbonyl)-1H-pyrazol-5-amine
   Show/Hide
C23H26FN5O
 1
1 IC50 = 1640 nM
CP0216155
1-(4-fluorophenyl)-4-({3-[3-(morpholin-4-yl)prop-1-yn-1-yl]phenyl}carbonyl)-1H-pyrazol-5-amine
   Show/Hide
C23H21FN4O2
 1
1 IC50 = 1720 nM
CP0263307
1-(4-fluorophenyl)-4-({3-[3-(morpholin-4-yl)propyl]phenyl}carbonyl)-1H-pyrazol-5-amine
   Show/Hide
C23H25FN4O2
 1
1 IC50 = 1740 nM
CP0166804
1-(4-fluorophenyl)-4-({3-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1H-pyrazol-5-amine
   Show/Hide
C23H25FN4O2
 1
1 IC50 = 1840 nM
CP0090234
4-({3-[3-(dimethylamino)prop-1-yn-1-yl]phenyl}carbonyl)-1-(4-fluorophenyl)-1H-pyrazol-5-amine
   Show/Hide
C21H19FN4O
 1
1 IC50 = 2280 nM
CP0508155
(5-Amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone
   Show/Hide
C16H13N3O
 1
1 IC50 = 2300 nM
CP0035385
4-{[3-(2-aminoethyl)phenyl]carbonyl}-1-(4-fluorophenyl)-1H-pyrazol-5-amine
   Show/Hide
C18H17FN4O
 1
1 IC50 = 2440 nM
CP0299368
4-benzoyl-1-(2-fluorophenyl)-1H-pyrazol-5-amine
   Show/Hide
C16H12FN3O
 1
1 IC50 = 2860 nM
CP0372062
1-(4-fluorophenyl)-4-({4-[3-(morpholin-4-yl)prop-1-yn-1-yl]phenyl}carbonyl)-1H-pyrazol-5-amine
   Show/Hide
C23H21FN4O2
 1
1 IC50 = 3130 nM
CP0255312
1-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenyl)ethane-1,2-diol
   Show/Hide
C18H16FN3O3
 1
1 IC50 = 3500 nM
CP0216156
3-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenyl)prop-2-yn-1-ol
   Show/Hide
C19H14FN3O2
 1
1 IC50 = 4040 nM
CP0490100
3-[5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carbonyl]-benzonitrile
   Show/Hide
C17H11FN4O
 1
1 IC50 = 4760 nM
CP0449578
4-benzoyl-1-(3-fluorophenyl)-1H-pyrazol-5-amine
   Show/Hide
C16H12FN3O
 1
1 IC50 = 6700 nM
CP0518021
4-benzoyl-1-(4-methoxyphenyl)-1H-pyrazol-5-amine
   Show/Hide
C17H15N3O2
 1
1 IC50 = 7060 nM
CP0034781
4-[5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carbonyl]benzonitrile
   Show/Hide
C17H11FN4O
 1
1 IC50 = 8380 nM
CP0506518
4-benzoyl-1-(2-methoxyphenyl)-1H-pyrazol-5-amine
   Show/Hide
C17H15N3O2
 1
1 IC50 = 8380 nM
CP0263415
2-(3-{[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbonyl}phenyl)propane-1,2,3-triol
   Show/Hide
C19H18FN3O4
 1
1 IC50 = 9540 nM
CP0816770
(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone O-methyloxime
   Show/Hide
C16H14N4O
 1
1 IC50 = 51000 nM
CP0334490
4-benzoyl-1-(3-nitrophenyl)-1H-pyrazol-5-amine
   Show/Hide
C16H12N4O3
 1
1 IC50 = 64200 nM
CP0031151
SR-301
   Show/Hide
C34H43N9O4S
 1
1 IC50 ~ 5390 nM
CP0029924
N-[[4-(3-cyclohexylpropylcarbamoyl)phenyl]methyl]-1-phenyl-5-(trifluoromethyl)pyrazole-4-carboxamide
   Show/Hide
C28H31F3N4O2
 1
1 IC50 ~ 13000 nM
CP0005166
BMS-354825
   Show/Hide
C22H26ClN7O2S
 2
1 Kd = 27 nM
2 Kd = 495 nM
CP0002230
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
   Show/Hide
C28H22F3N7O
 1
1 Kd = 460 nM
CP0071243
3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4'-carboxylic acid [4'-(cyclopropylmethyl-carbamoyl)-6-methyl-biphenyl-3-yl]-amide
   Show/Hide
C29H32N4O2
 2
1 Ki = 2.5 nM
2 Ki = 9 nM
CP0019121
N-[3-[4-(cyclopropylmethylcarbamoyl)phenyl]-4-methylphenyl]-2-morpholin-4-ylpyridine-4-carboxamide
   Show/Hide
C28H30N4O3
 2
1 Ki = 4.4 nM
2 Ki = 6 nM
Clinical Information about the Protein
Target 1 ( Stress-activated protein kinase 2a (p38 alpha) )
Target Type Clinical trial Target
Disease 8 Target-related Diseases  8
1 Acute coronary syndrome [ICD-11: BA41]
2 Coronary artery disease [ICD-11: BA80]
3 Rheumatoid arthritis [ICD-11: FA20]
4 Xerophthalmia [ICD-11: 5B55.Y]
5 Psoriasis vulgaris [ICD-11: EA90]
6 Arthritis [ICD-11: FA20]
7 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
8 Pain [ICD-11: MG30-MG3Z]
Approved Drug(s) 1 Approved Drug  1
1 Ozagrel Phase 4
Xerophthalmia
Clinical Trial Drug(s) 3 Clinical Trial Drugs  3
1 Losmapimod Phase 3
Acute coronary syndrome
2 VX-702 Phase 2a
Coronary artery disease
3 VX-745 Phase 2
Rheumatoid arthritis
Discontinued Drug(s) 6 Discontinued Drugs  6
1 PAMAPIMOD Discontinued in Phase 2
Rheumatoid arthritis
2 R-1487 Discontinued in Phase 1
Rheumatoid arthritis
3 SB 235699 Discontinued in Phase 1
Psoriasis vulgaris
4 SB-242235 Discontinued in Phase 1
Arthritis
5 SB220025 Terminated
Arthritis
6 SC-102 Terminated
Solid tumour/cancer
Investigative Drug(s) 2 Investigative Drugs  2
1 GW-788388 Investigative
Solid tumour/cancer
2 Oxindole 94 Investigative
Pain